ClinicaliQ Trial Snapshot
- A Study of Tirzepatide (LY3298176) Compared With Standard of Care in Adult Participants With Obesity and Without Diabetes (SURMOUNT-REAL UK) — Recruiting • Phase IV • Diabetes / Metabolic • NCT07247084.
- What is being tested: Tirzepatide (a dual GIP/GLP-1 receptor agonist) versus standard obesity care in a real-world UK setting, measuring weight loss and type 2 diabetes prevention in adults with obesity and weight-related comorbidities.
- Patient eligibility: Adults without diabetes who have obesity and at least one weight-related comorbid condition (such as hypertension, cardiovascular disease, or sleep apnoea), reflecting typical primary care populations rather than trial-selected cohorts.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to evaluate tirzepatide within a real-world setting to assess body weight loss and incidence of type 2 diabetes in adults without diabetes who have obesity and at least one weight-related comorbid condition. Participation in the study will last about 260 weeks.
Eligibility Snapshot
- : * Have a body mass index ≥30 and ≤34.9 kilogram per square meter (kg/m2) * Have an increased waist to height ratio (defined by >0.5) * Have at least one weight related comorbid condition * Have had at least one attempt to lose weight with lifestyle intervention (diet and physical activity)
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.